Tirzepatide vs semaglutide: what the head-to-head trials found

What is the difference between tirzepatide and semaglutide?

Both drugs belong to the same broad family — GLP-1 receptor agonists — and both are once-weekly injections that reduce appetite, slow the stomach and lower blood sugar. The core difference is how many receptors each one activates. Semaglutide is a modified copy of the human hormone GLP-1 and works through the single GLP-1 receptor. Tirzepatide is a purpose-built 39-amino-acid peptide that switches on two incretin receptors at once: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). That second receptor is the whole reason tirzepatide exists as a distinct drug.

The commercial picture reinforces the split. Semaglutide, made by Novo Nordisk, reached the market first and now sells under three names — Ozempic for type 2 diabetes, Wegovy for chronic weight management and cardiovascular risk reduction, and Rybelsus as an oral tablet for diabetes. Tirzepatide, made by Eli Lilly, arrived later as Mounjaro for diabetes and Zepbound for obesity and obstructive sleep apnea. Same weekly cadence, different molecules, different labels. Everything else in this comparison flows from that one mechanistic difference and the trials built to test it.

Mechanism: dual GIP/GLP-1 vs GLP-1 alone

GLP-1 is an incretin hormone released by intestinal L-cells after a meal. It boosts glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and signals fullness in the brainstem and hypothalamus — physiology mapped in detail long before any of these drugs were made (PubMed 17928588). Because the insulin effect is glucose-dependent, it eases off as blood sugar normalizes, which is why this whole class rarely causes hypoglycemia on its own. Semaglutide simply extends that natural signal: a fatty-acid chain binds albumin and stretches the half-life to about a week.

Tirzepatide adds GIP agonism on top. GIP is the other major incretin, and for years it was dismissed as therapeutically useless because GIP responsiveness looks blunted in type 2 diabetes. Tirzepatide challenged that view. Layering GIP activation onto GLP-1 appears to improve insulin sensitivity in fat tissue, influence lipid handling, and — through GIP receptors in the brain — reinforce appetite suppression while possibly softening the nausea signal. Reviews of incretin pharmacology stress that receptor selectivity, signaling bias and dose intensity all contribute, and that head-to-head trials, not mechanism alone, are the reliable guide to which drug does more (PubMed 33767808). The wider role of these gut hormones in appetite and metabolism is reviewed in PubMed 34067710.

The practical takeaway from mechanism is modest: dual agonism is a plausible reason to expect more from tirzepatide, but "more receptors" does not guarantee "better outcome" for any given person or any given endpoint. That is exactly why the head-to-head trials matter.

Tirzepatide vs semaglutide for weight loss

For years, comparisons relied on cross-trial math: tirzepatide's SURMOUNT-1 reported 20.9% mean weight loss on the 15 mg dose over 72 weeks (PubMed 35658024), while semaglutide's STEP 1 reported 14.9% over 68 weeks (PubMed 33567185). Different trials, different populations — suggestive, not conclusive.

SURMOUNT-5 removed the guesswork. It randomized 751 adults with obesity and without diabetes to maximum tolerated tirzepatide (10 or 15 mg) or maximum tolerated semaglutide (1.7 or 2.4 mg) and ran for 72 weeks. Mean weight reduction was 20.2% with tirzepatide versus 13.7% with semaglutide — a difference of about 6.5 percentage points in a single controlled comparison. And the gap widened at the deep end: 31.6% of the tirzepatide group lost at least a quarter of their body weight, versus 16.1% on semaglutide (PubMed 40353578).

Two honest caveats keep this in perspective. First, semaglutide's 13.7% here sits close to STEP 1's 14.9%, so SURMOUNT-5 did not sandbag the comparator. Second, this trial used the 2.4 mg semaglutide ceiling; higher-dose GLP-1 formulations tested since have narrowed, though not closed, the distance. On the specific question of average weight loss over 72 weeks, tirzepatide won a fair fight — a conclusion echoed by our overview of peptides studied for weight loss.

Tirzepatide vs semaglutide for type 2 diabetes

The glycemic head-to-head came earlier. SURPASS-2 randomized 1,879 adults with type 2 diabetes on metformin to tirzepatide 5, 10 or 15 mg or to semaglutide 1 mg for 40 weeks. Tirzepatide was noninferior and then superior on HbA1c at every dose, cutting it by roughly 2.0 to 2.3 percentage points versus about 1.9 for semaglutide, and it produced more weight loss — around 7.6 to 11.2 kg versus 5.7 kg (PubMed 34170647). A large share of tirzepatide participants reached an HbA1c below 5.7%, which is technically the non-diabetic range.

Two points prevent this from being a blowout. The trial compared against semaglutide 1 mg, not the 2.0 mg diabetes dose approved later, so the modern glycemic gap is smaller than SURPASS-2 suggests in isolation. And because both drugs work in a glucose-dependent way, hypoglycemia was uncommon in either arm unless combined with insulin or a sulfonylurea. For people whose primary goal is blood-sugar control, tirzepatide has the edge on the number — but semaglutide's diabetes track record and its heart data (below) are part of the same decision. The weight-in-diabetes picture is filled out by SURMOUNT-2, where tirzepatide produced 12.8% to 14.7% loss in people who also had type 2 diabetes (PubMed 37385275).

The numbers side by side

The table below lines up the two molecules across the dimensions people actually weigh when comparing them. It is a summary of published trial data, not a recommendation.

Side effects: which is better tolerated?

The two drugs share a side-effect fingerprint because they share a mechanism: the gut. Nausea, diarrhea, vomiting and constipation lead the list for both, are mostly mild to moderate, appear during dose escalation, and tend to settle at a stable dose. A systematic review and meta-analysis of tirzepatide trials quantified its side: nausea in 20.4% of users versus 10.5% of controls, diarrhea 16.2% versus 8.6%, vomiting 9.1% versus 4.9%, and constipation 2.5% versus 0.9% (PubMed 37908927). Semaglutide's rates fall in a similar range, and in weight-management dosing both drugs push nausea higher as the dose climbs.

Does one win on tolerability? In SURMOUNT-5, the head-to-head that matters, gastrointestinal events were common in both arms and broadly similar in character and frequency, and treatment discontinuation for adverse events stayed in the single digits for each drug. Some preclinical and network analyses hint that tirzepatide may provoke slightly less emesis per unit of weight loss, but that signal is not settled in humans. The practical reading: neither drug is clearly gentler, and the deciding factor is usually how an individual tolerates dose increases rather than the molecule itself.

Both also share the less common but clinically important signals — gallbladder disease (rapid weight loss of any kind raises gallstone risk), acute pancreatitis, injection-site reactions, and gastric emptying delayed enough to matter for anesthesia. Both labels carry the rodent thyroid C-cell tumor boxed warning and the same contraindication in people with a personal or family history of medullary thyroid carcinoma or MEN2. And with either drug, a meaningful fraction of weight lost is lean mass, which is why trial protocols paired them with diet and activity counseling.

Cardiovascular outcomes: SELECT vs SURPASS-CVOT

This is the dimension where semaglutide, not tirzepatide, holds the stronger hand — and it is the single biggest reason "better" is not a one-word answer. Weight loss is a surrogate; what many clinicians ultimately care about is whether a drug prevents heart attacks, strokes and deaths.

Semaglutide has direct, placebo-controlled proof. The SELECT trial enrolled 17,604 adults with established cardiovascular disease, a BMI of 27 or higher and no diabetes, and followed them for a mean near 40 months. Major adverse cardiovascular events — cardiovascular death, nonfatal heart attack or nonfatal stroke — occurred in 6.5% on semaglutide versus 8.0% on placebo, a hazard ratio of 0.80, or a 20% relative reduction (PubMed 37952131). That result is why Wegovy carries a cardiovascular risk-reduction indication.

Tirzepatide's evidence is newer and framed differently. SURPASS-CVOT randomized 13,299 adults with type 2 diabetes and atherosclerotic cardiovascular disease to tirzepatide or dulaglutide — an older GLP-1 agonist that already has proven cardiovascular benefit — and followed them for a median of about four years. The composite endpoint occurred in 12.2% on tirzepatide versus 13.1% on dulaglutide, a hazard ratio of 0.92 that met noninferiority but not superiority (PubMed 41406444). In plain terms: tirzepatide is at least as protective as an established GLP-1 agonist in that population, but it has not shown a placebo-beating event reduction the way semaglutide has. Two different questions, two different answers — and only one of them is a clean superiority result.

Cost, brands and access

On price, the two are more alike than different, and neither is cheap. US list prices for both have run above roughly $1,000 a month, and insurance coverage is inconsistent in the same frustrating way: many commercial plans cover the diabetes brand (Mounjaro, Ozempic) but exclude the obesity brand (Zepbound, Wegovy), and US Medicare Part D has historically been barred from covering drugs prescribed purely for weight loss. Manufacturer savings programs and direct-to-consumer self-pay vials have brought real costs down for some doses of each. Which is cheaper for a specific person usually comes down to their plan and the offers active that month, not the molecule.

Both drugs also spawned a large gray market during their shortages, when US compounding pharmacies were temporarily allowed to make copies. As the FDA declared each shortage resolved — tirzepatide in late 2024, semaglutide in early 2025 — that permission wound down, and routine mass compounding of both ended. What persists is unregulated vials sold online as "research chemicals" or "not for human consumption." These are not approved drugs, are subject to no pharmaceutical quality control, and independent testing of similar products has repeatedly found inconsistent content and purity. PepMate does not recommend or link to any source of peptides; for how the regulatory lines are drawn, see are peptides legal.

So which one is better?

The evidence points in two directions, and that is the honest answer. On average weight loss and blood-sugar lowering, tirzepatide won the direct comparisons — 20.2% versus 13.7% in SURMOUNT-5, and a larger HbA1c drop in SURPASS-2. On cardiovascular outcomes, semaglutide has the stronger, placebo-controlled proof from SELECT, while tirzepatide's SURPASS-CVOT only demonstrated noninferiority to an existing drug. Semaglutide also has more years of real-world use and an oral option for diabetes.

That means the "winner" depends entirely on the goal: maximum weight and glycemic effect points toward tirzepatide, while documented cardiovascular event reduction and a longer track record point toward semaglutide. Tolerability, insurance coverage, kidney function, other medications, and personal history all shift the balance further. None of those variables is something to self-adjudicate. The choice between these drugs — including dose, titration pace and whether either is appropriate at all — is a clinical decision made with a licensed prescriber. If you want the brand-versus-brand angle instead, see Mounjaro vs Ozempic, and for what may eclipse both, the triple agonist retatrutide vs tirzepatide (PubMed 37366315). Background on how incretin drugs are engineered is summarized in PubMed 31050435.

Whichever drug a clinician chooses, both behave like treatments for a chronic condition rather than a short course: when semaglutide was withdrawn after a lead-in, participants regained about two-thirds of their lost weight within a year and their cardiometabolic gains reversed with it (PubMed 35441470). Tirzepatide shows the same pattern on stopping. Which is a strong argument for tracking what actually happens on either drug, week to week.

Frequently asked questions

Sources

Every claim above traces to peer-reviewed literature indexed on PubMed:

1. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) — PubMed 40353578
2. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) — PubMed 34170647
3. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — PubMed 35658024
4. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — PubMed 33567185
5. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) — PubMed 37385275
6. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) — PubMed 37952131
7. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT) — PubMed 41406444
8. Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis — PubMed 37908927
9. Weight regain and cardiometabolic effects after withdrawal of semaglutide — PubMed 35441470
10. GLP-1 receptor agonists: an updated review of head-to-head clinical studies — PubMed 33767808
11. The physiology of glucagon-like peptide 1 — PubMed 17928588
12. The Role of Peptide Hormones Discovered in the 21st Century in the Regulation of Appetite and Metabolism — PubMed 34067710
13. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — PubMed 37366315
14. Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency — PubMed 31050435

Keep reading